Abstract β-Adrenergic receptor blockers (β-blockers) are well-known useful and cost-
effective drugs for managing hypertensive patients with coronary heart disease, stroke, and …

Background Hypertension complicated with left ventricular hypertrophy (LVH) and diastolic
dysfunction is one of the most common risks for heart failure with preserved ejection fraction …

Despite significant advances in pharmacologic approaches to treat hypertension during the
last decades, hypertension-and hypertension-related organ damage are still a high health …

A quantitative survey was completed by 103 primary care physicians (PCPs) and 59
cardiologists who regularly prescribed β‐blockers to assess knowledge and use of this …

Aim Potential heterogeneity within the same class of drug in terms of persistence may lead
to different clinical implications. Given that the increased risks of mortality and …

Objective: To compare adherence and persistence associated with nebivolol and
hydrochlorothiazide (HCTZ) as add-on hypertension treatments. Research design and …

Objective: To estimate the real-world economic impact of switching hypertensive patients
from metoprolol, a commonly prescribed, generic, non-vasodilatory β 1-blocker, to nebivolol …

Objectives: To assess the association between medical costs and persistence with beta
blockers among hypertensive patients, and to quantify persistence related medical cost …

Background The prevalence of hypertension is increasing in the United States and the
associated costs are soaring. Despite the many treatment options, only approximately 50 …

Real‐world tolerability and effectiveness of nebivolol as first add‐on therapy were compared
with hydrochlorothiazide, metoprolol, and amlodipine. Medical records of hypertensive …